Gossamer Bio is trading 10.35% down at $8.92, with no company-specific headline identified for November 5, 2026; the move coincides with a sharp biotech and broader risk-sensitive stock selloff.
- Schwab’s stock page also showed no headlines for November 5, 2026.
- November 5 reporting described pressure on technology and AI-related shares amid regulatory concerns following the U.S. midterm elections; this is broader market context, not a Gossamer Bio-specific catalyst.